Table 1.

Patient demographics and baseline disease characteristics by USP-11 groups

		USP11 Low (N=40)	USP11 High (N=16)	P
Age
	≤ 50	18 (45%)	5 (31.3%)	0.38
	>50	22 (55%)	11 (68.8%)
Race
	White	32 (80%)	10 (62.5%)	0.82
	Black	2 (5%)	2 (12.5%)
	Hispanic	5 (12.5%)	2 (12.5%)
	Other	1 (2.5%)	2 (12.5%)
Clinical tumor stage
	T1	7 (17.5%)	3 (18.8%)	0.04
	T2	20 (50%)	4 (25%)
	T3	9 (22.8%)	2 (12.5%)
	T4	4 (10%)	7 (43.8%)
Clinical nodal stage
	N0	14 (35%)	6 (37.5%)	0.86
	N1-3	26 (65%)	10 (62.5%)
Clinical stage
	I	2 (5%)	1 (6.3%)	0.29
	II	24 (60%)	6 (37.5%)
	III	13 (32.5%)	9 (56.5%)
	IV	1 (2.5%)	-
ER status
	Negative	20 (50%)	7 (43.8%)	0.67
	Positive	20 (50%)	9 (56.3%)
PR status
	Negative	23 (57.5%)	8 (50%)	0.61
	Positive	17 (42.5%)	13 (50%)
HER2 status
	Negative	28 (70%)	13 (81.3%)	0.51
	Positive	12 (30%)	3 (18.8%)
Triple negative status
	No	32 (80%)	12 (75%)	0.72
	Yes	8 (20%)	4 (25%)
Nuclear grade
	I–II	9 (22.5%)	6 (37.5%)	0.25
	III	31 (77.5%)	10 (62.5%)
Lymphatic invasion
	Negative	31 (77.5%)	8 (50%)	0.04
	Positive	9 (22.5%)	8 (50%)
Vascular invasion
	Negative	55 (96.5%)	8 (50%)	0.01
	Positive	2 (3.5%)	8 (50%)
Skin involvement
	Negative	38 (95%)	15 (93.8%)	1.00
	Positive	2 (5%)	1 (6.3%)

ER= estrogen receptor; PR=progesterone receptor; HER2 = human epidermal growth factor receptor-2